Date: 2014-01-06
Type of information: Grant
Company: Scancell Holdings (UK)
Investors: Nottingham City Council (UK)
Amount: £80,000 (€ 96,318)
Funding type: grant
Planned used: Scancell will use the funds to secure additional staff to develop its groundbreaking new Moditope® technology platform.
Others: * On January 6, 2014, Scancell Holdings, a developer of immunotherapies for the treatment of cancer, has announced that it has received a Nottingham Technology Grant Fund (”N’Tech”) of £80,000 from Nottingham City Council. Funded by the Government’s Regional Growth Fund, the grants from N’Tech are awarded mainly to small and medium-sized companies to support business growth and expansion in the Greater Nottingham area. Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms. Scancell’s first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and has just completed Phase 1/2 clinical trials which demonstrated that SCIB1 produced a melanoma-specific immune response and promising survival trend. A further higher dose study of SCIB1 will
take place during 2014.
Therapeutic area: Cancer - Oncology
